# Pradefovir Treatment for the Patients With Chronic Hepatitis B Virus Infections: a Phase3 Study

> **NCT04543565** · PHASE3 · UNKNOWN · sponsor: **Xi'an Xintong Pharmaceutical Research Co.,Ltd.** · enrollment: 900 (estimated)

## Conditions studied

- Chronic Hepatitis b

## Interventions

- **DRUG:** Pradefovir Mesylate;Placebo of Tenofovir disoproxil fumarate tablet
- **DRUG:** Tenofovir disoproxil fumarate tablet;Placebo of Pradefovir Mesylate

## Key facts

- **NCT ID:** NCT04543565
- **Lead sponsor:** Xi'an Xintong Pharmaceutical Research Co.,Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09
- **Primary completion:** 2022-10
- **Final completion:** 2024-12
- **Target enrollment:** 900 (ESTIMATED)
- **Last updated:** 2020-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04543565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04543565, "Pradefovir Treatment for the Patients With Chronic Hepatitis B Virus Infections: a Phase3 Study". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT04543565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*